I wonder if any efforts have been made to conduct a deep review of clinical trials to see if there are patterns of protocol design that are likely to lead to underreporting of adverse effects.
As (unfortunately) a user of a number of prescription medications, I have encountered adverse effects that were considered uncommon, yet heard about similar issues from fellow users. Of course, this is anecdata, so one can draw no conclusions, but I have a nagging suspicion that enough digging by people who truly understand statistics will find flaws, perhaps major ones.
As (unfortunately) a user of a number of prescription medications, I have encountered adverse effects that were considered uncommon, yet heard about similar issues from fellow users. Of course, this is anecdata, so one can draw no conclusions, but I have a nagging suspicion that enough digging by people who truly understand statistics will find flaws, perhaps major ones.
Not likely to happen, though.